TRIAL DETAIL

A Study Evaluating GDC-0980 Administered Once Weekly in Patients With Refractory Solid Tumors or Non-Hodgkin's Lymphoma

Drug:
Trial Name:
A Study Evaluating GDC-0980 Administered Once Weekly in Patients With Refractory Solid Tumors or Non-Hodgkin's Lymphoma
NCT#:
Conditions:
Solid Tumors
Status:
Ongoing, but not recruiting
Phase:
1
Start Date 04/01/2009
Age of Trial (yrs) 13.2
Treatment Phase:
Gleevec-resistant
Drug Category:
PI3K inhibitor + mTOR inhibitor
Strategy:
Block KIT Signal Path
Trial Type:
GIST not specified. GIST patients known to be enrolled.
Other Protocol IDs:
PIM4605g
Sponsor:
Genentech
Patient Contact:
Christiaan McEwen mcewen.christiaan@gene.com
Contact email:
Contact Phone:
Randomized:
IV or Oral:
Oral
Trial Notes:

Trial Links

Trial Results

Drug Information

Genentech website - pipeline drug description
 
ASCO phase 1 results
 
Pharmacokinetics and pharmacodynamic biomarkers for the dual PI3K/mTOR inhibitor GDC-0980: Initial phase I evaluation
 

Trial Sites

Name
Address
City
State
Zip
Country
450 Brookline Ave
Boston
MA
02215-5450
USA
Villejuif
Val de Narne
94805
France
550 Wilmslow Rd
Manchester
Lancashire
M20 4BX
UK